NCT00319982View on ClinicalTrials.gov

Treatment of Preclinical Hypertrophic Cardiomyopathy With Diltiazem

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

January 31, 2006

Primary Completion Date

December 31, 2012

Study Completion Date

December 31, 2013

Conditions
Hypertrophic Cardiomyopathy
Interventions
DRUG

Diltiazem

Sustained release formulation titrated to a target dose of 360 mg daily, or a maximum of 5 mg/kg/day in pediatric subjects for the duration of the study period

DRUG

Placebo

Placebo comparator (double-blind allocation of study medication)

Trial Locations (2)

02115

Brigham and Women's Hospital, Boston

Children's Hospital, Boston

All Listed Sponsors
collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

collaborator

Boston Children's Hospital

OTHER

lead

Brigham and Women's Hospital

OTHER

NCT00319982 - Treatment of Preclinical Hypertrophic Cardiomyopathy With Diltiazem | Biotech Hunter | Biotech Hunter